{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:53:20Z","timestamp":1791305600190,"version":"4.3.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1016\/j.leukres.2005.08.006","type":"journal-article","created":{"date-parts":[[2005,9,22]],"date-time":"2005-09-22T11:21:12Z","timestamp":1127388072000},"page":"415-426","source":"Crossref","is-referenced-by-count":38,"title":["A Fas agonist induces high levels of apoptosis in haematological malignancies"],"prefix":"10.1016","volume":"30","author":[{"given":"Peter","family":"Greaney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimable","family":"Nahimana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucienne","family":"Lagopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Lise","family":"Etter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Aubry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Attinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Beltraminelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Huni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Bassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Sordat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Demotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Dupuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel A.","family":"Duchosal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.leukres.2005.08.006_bib1","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/sj.cdd.4400943","article-title":"Insights into cancer therapeutic design based on p53 and TRAIL receptor signalling","volume":"8","author":"El-Deiry","year":"2001","journal-title":"Cell Death Differ"},{"issue":"1","key":"10.1016\/j.leukres.2005.08.006_bib2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0145-2126(00)00085-0","article-title":"Drug resistance does not correlate with resistance to Fas-mediated apoptosis","volume":"25","author":"Cullen","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2005.08.006_bib3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1006\/excr.2000.4840","article-title":"The CD95 (APO-1\/Fas) and the TRAIL (APO-2L) apoptosis systems","volume":"256","author":"Walczak","year":"2000","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.leukres.2005.08.006_bib4","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0065-2776(08)60588-X","article-title":"Cytotoxic T lymphocytes: the newly identified Fas (CD95)-mediated killing mechanism and a novel aspect of their biological functions","volume":"60","author":"Takayama","year":"1995","journal-title":"Adv Immunol"},{"key":"10.1016\/j.leukres.2005.08.006_bib5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0065-2776(08)60402-2","article-title":"CD95(APO-1\/Fas)-mediated apoptosis: live and let die","volume":"71","author":"Krammer","year":"1999","journal-title":"Adv Immunol"},{"issue":"4","key":"10.1016\/j.leukres.2005.08.006_bib6","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1128\/MCB.23.4.1428-1440.2003","article-title":"Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex","volume":"23","author":"Holler","year":"2003","journal-title":"Mol Cell Biol"},{"issue":"2","key":"10.1016\/j.leukres.2005.08.006_bib7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/path.1028","article-title":"Fas receptor-mediated apoptosis: a clinical application?","volume":"196","author":"Timmer","year":"2002","journal-title":"J Pathol"},{"issue":"12","key":"10.1016\/j.leukres.2005.08.006_bib8","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1182\/blood.V85.12.3566.bloodjournal85123566","article-title":"Expression and function of Fas (APO-1\/CD95) in patient myeloma cells and myeloma cell lines","volume":"85","author":"Westendorf","year":"1995","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2005.08.006_bib9","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1182\/blood.V85.3.757.bloodjournal853757","article-title":"Myeloma cells express Fas antigen\/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis","volume":"85","author":"Shima","year":"1995","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2005.08.006_bib10","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0145-2126(99)00203-9","article-title":"Qualitative and quantitative characterization of Fas (CD95) expression and its role in primary human acute leukemia cells","volume":"24","author":"Li","year":"2000","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.leukres.2005.08.006_bib11","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1046\/j.1365-2141.1996.d01-1719.x","article-title":"Expression of Fas antigen in acute myeloid leukaemia is associated with therapeutic response to chemotherapy","volume":"93","author":"Min","year":"1996","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.leukres.2005.08.006_bib12","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1182\/blood.V90.12.4901","article-title":"Functional expression of Fas (CD95) in acute myeloid leukemia cells in the context of CD34 and CD38 expression: possible correlation with sensitivity to chemotherapy","volume":"90","author":"Iijima","year":"1997","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.leukres.2005.08.006_bib13","doi-asserted-by":"crossref","first-page":"6611","DOI":"10.1073\/pnas.0400765101","article-title":"Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death","volume":"101","author":"Dutton","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.leukres.2005.08.006_bib14","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1182\/blood.V94.5.1727","article-title":"Modulation of caspase-8 and FLICE-inhibitory protein expression as a potential mechanism of Epstein-Barr virus tumorigenesis in Burkitt's lymphoma","volume":"94","author":"Tepper","year":"1999","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2005.08.006_bib15","first-page":"696","article-title":"Bax is frequently compromised in Burkitt's lymphomas with irreversible resistance to Fas-induced apoptosis","volume":"59","author":"Gutierrez","year":"1999","journal-title":"Cancer Res"},{"issue":"18","key":"10.1016\/j.leukres.2005.08.006_bib16","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0960-9822(07)00420-4","article-title":"Essential requirement for caspase-8\/FLICE in the initiation of the Fas-induced apoptotic cascade","volume":"8","author":"Juo","year":"1998","journal-title":"Curr Biol"},{"issue":"2\u20133","key":"10.1016\/j.leukres.2005.08.006_bib17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0014-2999(02)01430-9","article-title":"ACRP30, a new hormone controlling fat and glucose metabolism","volume":"440","author":"Tsao","year":"2002","journal-title":"Eur J Pharmacol"},{"issue":"Suppl. 1","key":"10.1016\/j.leukres.2005.08.006_bib18","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/stem.5530150826","article-title":"Assay of human stem cells by repopulation of NOD\/SCID mice","volume":"15","author":"Dick","year":"1997","journal-title":"Stem Cells"},{"issue":"2","key":"10.1016\/j.leukres.2005.08.006_bib19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0301-472X(00)00623-8","article-title":"Mutation analysis of the FAS and TNFR apoptotic cascade genes in hematological malignancies","volume":"29","author":"Rozenfeld-Granot","year":"2001","journal-title":"Exp Hematol"},{"issue":"7","key":"10.1016\/j.leukres.2005.08.006_bib20","first-page":"1227","article-title":"Expression and function of the FAS antigen in B chronic lymphocytic leukemia and hairy cell leukemia","volume":"9","author":"Panayiotidis","year":"1995","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.leukres.2005.08.006_bib21","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1046\/j.1365-2141.1997.4963301.x","article-title":"Quantitative characterization and potential function of membrane Fas\/APO-1 (CD95) receptors on leukaemic cells from chronic B and T lymphoid leukaemias","volume":"99","author":"Kamihira","year":"1997","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.leukres.2005.08.006_bib22","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1046\/j.1365-2141.1997.422688.x","article-title":"Role of the CD40 and CD95 (APO-1\/Fas) antigens in the apoptosis of human B-cell malignancies","volume":"97","author":"Wang","year":"1997","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.leukres.2005.08.006_bib23","first-page":"335","article-title":"Molecular determinants of response to TRAIL in killing of normal and cancer cells","volume":"6","author":"Kim","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.leukres.2005.08.006_bib24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0145-2126(98)00158-1","article-title":"Qualitative and quantitative characterization of Fas (APO-1\/CD95) on leukemic cells derived from patients with B-cell neoplasms","volume":"23","author":"Tsuruda","year":"1999","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.leukres.2005.08.006_bib25","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s001090050351","article-title":"Molecular pathogenesis of chronic lymphocytic leukemia: factors and signaling pathways regulating cell growth and survival","volume":"77","author":"Meinhardt","year":"1999","journal-title":"J Mol Med"},{"issue":"2","key":"10.1016\/j.leukres.2005.08.006_bib26","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1172\/JCI200522094","article-title":"Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis","volume":"115","author":"Contri","year":"2005","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.leukres.2005.08.006_bib27","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0145-2126(01)00063-7","article-title":"Upstream mediators of the Fas apoptotic transduction pathway are defective in B-chronic lymphocytic leukemia","volume":"25","author":"Roue","year":"2001","journal-title":"Leuk Res"},{"issue":"44","key":"10.1016\/j.leukres.2005.08.006_bib28","doi-asserted-by":"crossref","first-page":"6809","DOI":"10.1038\/sj.onc.1205853","article-title":"Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia","volume":"21","author":"MacFarlane","year":"2002","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.leukres.2005.08.006_bib29","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s10059-000-0552-0","article-title":"FLIP is constitutively hyperexpressed in Fas-resistant U266 myeloma cells, but is not induced by IL-6 in Fas-sensitive RPM18226 cells","volume":"10","author":"Kim","year":"2000","journal-title":"Mol Cells"},{"issue":"6","key":"10.1016\/j.leukres.2005.08.006_bib30","first-page":"417","article-title":"Induction of apoptosis\u2014new targets for cancer chemotherapy","volume":"3","author":"Dive","year":"1992","journal-title":"Semin Cancer Biol"},{"issue":"6","key":"10.1016\/j.leukres.2005.08.006_bib31","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1182\/blood.V89.6.1845","article-title":"Apoptosis and the dilemma of cancer chemotherapy","volume":"89","author":"Hannun","year":"1997","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2005.08.006_bib32","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1600-0609.1994.tb01284.x","article-title":"Induction of apoptosis in childhood acute leukemia by chemotherapeutic agents: failure to detect evidence of apoptosis in vivo","volume":"52","author":"Matsubara","year":"1994","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.leukres.2005.08.006_bib33","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1038\/sj.onc.1207558","article-title":"Death receptors in chemotherapy and cancer","volume":"23","author":"Debatin","year":"2004","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.leukres.2005.08.006_bib34","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1182\/blood.V93.6.1992.406k23_1992_2002","article-title":"CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells","volume":"93","author":"Buhmann","year":"1999","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2005.08.006_bib35","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jlb.67.1.2","article-title":"CD40\u2013CD40 ligand","volume":"67","author":"van Kooten","year":"2000","journal-title":"J Leukoc Biol"},{"issue":"9","key":"10.1016\/j.leukres.2005.08.006_bib36","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1182\/blood.V96.9.2917","article-title":"CD40\u2013ligand (CD154) gene therapy for chronic lymphocytic leukemia","volume":"96","author":"Wierda","year":"2000","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2005.08.006_bib37","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1080\/1042819031000111026","article-title":"Effects of preactivated autologous T lymphocytes on CD80, CD86 and CD95 expression by chronic lymphocytic leukemia B cells","volume":"44","author":"Romano","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.leukres.2005.08.006_bib38","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.imlet.2004.09.022","article-title":"Induction of CD95 upregulation does not render chronic lymphocytic leukemia B-cells susceptible to CD95-mediated apoptosis","volume":"97","author":"Romano","year":"2005","journal-title":"Immunol Lett"},{"issue":"Suppl. C","key":"10.1016\/j.leukres.2005.08.006_bib39","first-page":"95","article-title":"Modulation of death receptor pathways in oncology","volume":"39","author":"de Vries","year":"2003","journal-title":"Drugs Today (Barc)"},{"issue":"4915","key":"10.1016\/j.leukres.2005.08.006_bib40","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.2787530","article-title":"Monoclonal antibody-mediated tumor regression by induction of apoptosis","volume":"245","author":"Trauth","year":"1989","journal-title":"Science"},{"issue":"6440","key":"10.1016\/j.leukres.2005.08.006_bib41","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/364806a0","article-title":"Lethal effect of the anti-Fas antibody in mice","volume":"364","author":"Ogasawara","year":"1993","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.leukres.2005.08.006_bib42","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","article-title":"Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma","volume":"102","author":"van Besien","year":"2003","journal-title":"Blood"},{"issue":"8837","key":"10.1016\/j.leukres.2005.08.006_bib43","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0140-6736(93)92560-G","article-title":"Gene-marking to trace origin of relapse after autologous bone-marrow transplantation","volume":"341","author":"Brenner","year":"1993","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.leukres.2005.08.006_bib44","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1182\/blood.V83.10.3068.3068","article-title":"Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML","volume":"83","author":"Deisseroth","year":"1994","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2005.08.006_bib45","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/sj.bmt.1700670","article-title":"Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation","volume":"19","author":"Gertz","year":"1997","journal-title":"Bone Marrow Transplant"},{"issue":"26","key":"10.1016\/j.leukres.2005.08.006_bib46","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma","volume":"349","author":"Attal","year":"2003","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.leukres.2005.08.006_bib47","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V89.3.789","article-title":"Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma","volume":"89","author":"Barlogie","year":"1997","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2005.08.006_bib48","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1634\/stemcells.20-2-174","article-title":"Human CD34+ hematopoietic stem\/progenitor cells express high levels of FLIP and are resistant to Fas-mediated apoptosis","volume":"20","author":"Kim","year":"2002","journal-title":"Stem Cells"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212605003140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212605003140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T20:56:28Z","timestamp":1586465788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212605003140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["S0145212605003140"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2005.08.006","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2006,4]]}}}